Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer
about
MiR-200c and HuR in ovarian cancerCurrent Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted TherapyNanoparticle-mediated drug delivery for treating melanomaMicrotubule-binding agents: a dynamic field of cancer therapeutics.Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discoveryHigh expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancerClass III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancerExpression of Tubb3, a beta-tubulin isotype, is regulated by androgens in mouse and rat Sertoli cellsβIII-Tubulin: biomarker of taxane resistance or drug target?Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerSpecific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cellsEvolution of resistance to Aurora kinase B inhibitors in leukaemia cellsLet-7 Sensitizes KRAS Mutant Tumor Cells to ChemotherapyP-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patientsClass III beta-tubulin expression and in vitro resistance to microtubule targeting agents.A novel synthetic 1,3-phenyl bis-thiourea compound targets microtubule polymerization to cause cancer cell death.Identification of β-tubulin as a common immunogen in gastrointestinal malignancy by mass spectrometry of colorectal cancer proteome: implications for early disease detection.Movers and shakers: cell cytoskeleton in cancer metastasis.Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.Src family kinases and paclitaxel sensitivity.βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancerβIII-Tubulin Regulates Breast Cancer Metastases to the Brain.Mechanisms of resistance to cabazitaxel.Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapyComparative proteomic analysis of paclitaxel resistance-related proteins in human breast cancer cell lines.Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study.Altered TUBB3 expression contributes to the epothilone response of mitotic cells.Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells.Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells.Increased levels of a unique post-translationally modified betaIVb-tubulin isotype in liver cancerTubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.A label-free mass spectrometry method for the quantification of protein isotypes.SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers.The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms.2-(m-Azidobenzoyl)taxol binds differentially to distinct β-tubulin isotypesDelineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids.Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
P2860
Q21261258-203CB90C-B4C8-4F11-A7CE-4AAE67105ED9Q26783432-B337D625-5DDC-4C23-BEF0-FA924DBA5859Q26798379-103E163C-F3B2-4B72-AA0B-833561B6A00CQ27690249-92A8B27C-C912-4DDB-BF5D-E2A8BD5824E3Q27702294-78A5FAB8-A39F-4AD0-A45A-4B1A6D06D43DQ27851983-B4B67056-C186-4FEE-B672-7E507056CD14Q28236320-765A1D1F-C94C-4CF3-AD04-801C0F938DF8Q28242579-D67B0076-824A-4E5C-A4D0-8182875E28A7Q28284878-4CEFB5F6-12B1-443A-AE57-374606DEB7D8Q28396304-5CFD761C-158E-4A2F-B540-D120B844272CQ28478885-A0D0A8C0-8245-4741-A037-F03A8B08AF0CQ28480926-1D73930E-6A0B-4783-B5A2-DF2061444F75Q28547017-159F97BA-60EC-4E24-AB0E-FBD2740D8C51Q33472987-700EF89E-1C51-4526-AB90-6CC048CE294FQ33630855-C851EE53-BF84-4F1C-8870-40E06DDE5B37Q33911201-757FFA80-7F43-4653-802D-FA134188AA72Q34136862-D6D385CB-A08C-4A22-9723-6C5639317750Q34914057-ECE2A510-880D-4BB0-B76A-F61B561B0EF7Q35172172-4B685BCB-4CDA-4BF0-8EC1-F2A96CD81116Q35214722-672B85A5-43CF-4345-93F4-ECE17135F927Q35273536-B9CC17F0-CD25-4856-93FA-01F822112EA5Q35587344-D391C9D0-0BE0-43C4-9A5D-A5E65B0F3C7AQ35661531-3970B336-5D4B-492E-AE19-D799646909E5Q35747285-2C5BB228-BAC0-4C84-B6C6-484DC25B4C2BQ35916938-71F52E52-93E2-404C-A160-B1D067650635Q36260567-9BE2633F-2D69-4176-91A2-995BF9FF3E99Q36411072-5BDE15D3-57F4-463E-B124-F87AD640F234Q36502964-082CADAA-D539-436D-9E21-4BC1BD0A3FC3Q36557893-CE102371-1AAA-4ABA-8D0A-30340B086896Q36678312-70DC9704-53A0-4BF9-B01D-7B4A06396DB8Q36804849-5D2B4097-2244-453D-804B-74C8EAD2DA3DQ36952750-4D48701B-42F5-4D6E-91C3-0850E3AD2070Q36980135-61251420-74A7-40CE-8519-1E73F44FF41DQ37013235-82E05200-B816-4792-B5C1-71B32D24B2D1Q37246242-1158446C-F109-40AC-BD5C-B73A5C27D3E8Q37306809-705ED296-1879-4DA6-B02E-DB387C44BC21Q37323043-5D25EB05-F61B-4CF0-8B60-CE2CA210BD63Q37447324-D67A3A7D-EE2E-42FB-87F0-BEC1C1BF4283Q37570220-756AB281-F352-47F1-A465-549C16A2CC8BQ37625835-44472501-7F18-4269-BEED-CAB586BB3803
P2860
Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Class III beta-tubulin mediate ...... in non small cell lung cancer
@ast
Class III beta-tubulin mediate ...... in non small cell lung cancer
@en
Class III beta-tubulin mediate ...... in non small cell lung cancer
@nl
type
label
Class III beta-tubulin mediate ...... in non small cell lung cancer
@ast
Class III beta-tubulin mediate ...... in non small cell lung cancer
@en
Class III beta-tubulin mediate ...... in non small cell lung cancer
@nl
prefLabel
Class III beta-tubulin mediate ...... in non small cell lung cancer
@ast
Class III beta-tubulin mediate ...... in non small cell lung cancer
@en
Class III beta-tubulin mediate ...... in non small cell lung cancer
@nl
P1433
P1476
Class III beta-tubulin mediate ...... in non small cell lung cancer
@en
P2093
Maria Kavallaris
Pei Pei Gan
P304
P356
10.1158/0008-5472.CAN-07-0509
P407
P577
2007-10-01T00:00:00Z